Embecta Corp.

Embecta Corp.

EMBCNYSE / NASDAQHealthcareSmall cap

$6.02-$0.17 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$202.3M
P/E
2.1x
EV / EBITDA
4.9x
Revenue
$1.1B
Net margin
8.8%
ROCE
35.7%

This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Embecta Corp. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-6.2%
3M
+10.1%
6M
+96.7%
1Y
Hidden
5Y
Short history
  • This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
  • A period is left blank when the price history is shorter than the period.

52-week range

This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.17 (-2.7%) from $6.19 to $6.02 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in EMBC, bought on each weekday since 2022.

News & filings

What Embecta filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Return on capital employed of 35.7%.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.
  • This period includes a one-day price step on 5 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Sector
Healthcare
Shares outstanding
58.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$202.3M
P/E
2.1x
P/B
-0.3x
EV / EBITDA
4.9x
EV / Sales
1.3x
P/S
0.2x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
27.4%
Net margin
8.8%
EBITDA margin
26.3%
ROE
-14.6%
ROCE
35.7%
ROA
8.7%
Asset turnover
0.99

Growth

Revenue
$1.1B
Revenue growth, 1Y
-3.8%
Revenue CAGR, 3Y
-1.5%
Net profit growth, 1Y
21.8%
Free cash flow
$182.4M

Solvency

Current ratio
2.41
Debt / Equity
-2.20
Debt / Assets
1.31
CFO / Net profit
2.01
Cash / Market cap
111.5%

Where the revenue went

Of every $100 of FY2025 revenue, $9 was left as net income.

Embecta Corp. income statement flow, FY2025
Embecta Corp. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$403.6M
RevenueGross profit$676.8M
Gross profitResearch and development$37.3M
Gross profitSelling, general and administrative$332.0M
Gross profitOther operating expenses$11.1M
Gross profitOperating income$296.4M
Operating incomePretax income$136.3M
Operating incomeInterest and other expense$160.1M
Pretax incomeTax and other$40.9M
Pretax incomeNet income$95.4M

Revenue and net profit

Revenue fell 3.8% in FY2025; net profit is the dashed line.

Embecta Corp. revenue and net profit by fiscal year
Embecta Corp. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.1B$223.6M
FY2023$1.1B$70.4M
FY2024$1.1B$78.3M
FY2025$1.1B$95.4M

Cash flows

FY2025: $191.7M from operations, $182.4M free after investment (dashed).

Embecta Corp. operating and free cash flow by fiscal year
Embecta Corp. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$412.2M$388.2M
FY2023$67.7M$41.2M
FY2024$35.7M$19.9M
FY2025$191.7M$182.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.1B-3.8%1Y
EBITDA
$284.3M+47.5%1Y
Net profit
$95.4M+21.8%1Y
Cash from operations
$191.7M+437.0%1Y
Free cash flow
$182.4M+816.6%1Y
Revenue CAGR, 3Y
-1.5%
Net profit CAGR, 3Y
-24.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.1B$284.3M$95.4M$182.4M-14.6%-3.8%+21.8%

Monthly returns

Month-by-month returns of EMBC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$1.7B
Equity-$651.2M
Paid-in capital$80.0M
Retained earnings-$445.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; EMBC highlighted.

P/E against peers

EMBC trades at 2.1x earnings against a peer median of -5.2x.

  1. Embecta Corp. (this company)2.1x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Embecta Corp.EMBCthis company$202.3M2.1x-0.3x-14.6%4.9x
Atrium Therapeutics, Inc.RNA$210.4M-2.7x1.0x-37.0%0.7x
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
Sanara MedTech Inc.SMTI$202.7M-5.4x34.1x-632.5%22.7x
TriSalus Life Sciences, Inc.TLSI$202.7M-5.2x-6.0x115.8%-6.6x
Alector, Inc.ALEC$201.0M—6.6x-466.3%—
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
Peer median—-5.2x1.2x-35.2%0.7x

Year-to-date ROI

EMBC since 1 January, against earlier years.

Historical volatility

EMBC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Embecta Corp. operating margin by fiscal year
Embecta Corp. operating margin by fiscal year
DateOperating margin
FY202232.6%
FY202320.0%
FY202425.4%
FY202527.4%
LineFY2025
Cost of revenueCost Of Revenue$403.6M
Gross profitGross Profit$676.8M
Operating expensesOperating Expense$380.4M
Research and developmentResearch And Development$37.3M
Other operating expensesOther Operating Expenses$700.0k
Depreciation and amortisationDepreciation And Amortization In Income Statement$10.4M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$10.4M
Amortization$10.4M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$10.4M
Total expensesTotal Expenses$784.0M
Pretax incomePretax Income$136.3M

Learn while you research

Academy chapters picked for Embecta Corp. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 2.1 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →